Oxford Index Search Results

You are looking at 1-10 of 1,457 items for:

Gore x clear all

Refine by subject


Refine by type

Refine by product


Platelet-Rich Fibrin Improves the Viability of Diced Cartilage Grafts in a Rabbit Model

Ali Göral, Cem Aslan, Betül Bolat Küçükzeybek, Dağhan Işık, Mübin Hoşnuter and Mustafa Durgun.

in Aesthetic Surgery Journal

April 2016; p ublished online March 2016 .

Journal Article. Subjects: Dermatology; Surgery; Plastic and Reconstructive Surgery. 4741 words.


Diced cartilage may be wrapped with synthetic or biological materials before grafting to a recipient site. These materials have unique advantages...

Go to Oxford Journals »  home page

Methods to Assess Population Effectiveness of Therapies in Human Immunodeficiency Virus Incident and Prevalent Cohorts

Patrick M. Tarwater, John Mellors, Mary E. Gore, Joseph B. Margolick, John Phair, Roger Detels and Alvaro Muñoz.

in American Journal of Epidemiology

October 2001; p ublished online October 2001 .

Journal Article. Subjects: Public Health and Epidemiology. 4983 words.

Two methods are presented for measuring population effectiveness (i.e., reduction of disease in a population in which only some receive treatment) of antiretroviral therapy among human...

Go to Oxford Journals »  abstract

Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma

L. Spain, R. Higgins, K. Gopalakrishnan, S. Turajlic, M. Gore and J. Larkin.

in Annals of Oncology

June 2016; p ublished online March 2016 .

Journal Article. Subjects: Medical Oncology. 2005 words.

Immune checkpoint inhibitors such as ipilimumab and nivolumab improve survival in patients with advanced melanoma and are increasingly available to clinicians for use in the clinic. Their...

Go to Oxford Journals »  home page

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

B. Melichar, S. Bracarda, V. Matveev, B. Alekseev, S. Ivanov, A. Zyryanov, R. Janciauskiene, E. Fernebro, P. Mulders, S. Osborne, S. Jethwa, G. Mickisch, M. Gore, R. J. A. van Moorselaar, M. Staehler, N. Magne and J. Bellmunt.

in Annals of Oncology

September 2013; p ublished online June 2013 .

Journal Article. Subjects: Medical Oncology. 3432 words.


Avastin and Roferon in Renal Cell Carcinoma (AVOREN) demonstrated efficacy for bevacizumab plus interferon-α2a (IFN; 9 MIU tiw) in first-line...

Go to Oxford Journals »  abstract

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer

G. Rustin, N. Reed, G. C. Jayson, J. A. Ledermann, M. Adams, T. Perren, C. Poole, M. Lind, M. Persic, S. Essapen, M. Gore, H. Calvert, C. Stredder, A. Wagner, M. Giurescu and S. Kaye.

in Annals of Oncology

November 2011; p ublished online March 2011 .

Journal Article. Subjects: Medical Oncology. 3768 words.

Background: Sagopilone, the first fully synthetic epothilone, has shown promising preclinical activity in tumour models. This open-label randomised phase II study investigated...

Go to Oxford Journals »  abstract

Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study

C. Fotopoulou, I. Vergote, P. Mainwaring, M. Bidzinski, J. B. Vermorken, S. A. Ghamande, P. Harnett, S. A. Del Prete, J. A. Green, M. Spaczynski, S. Blagden, M. Gore, J. Ledermann, S. Kaye and H. Gabra.

in Annals of Oncology

January 2014; p ublished online December 2013 .

Journal Article. Subjects: Medical Oncology. 3608 words.


Platinum-resistant ovarian cancer (PROC) constitutes a therapeutic dilemma with limited efficacy from traditional cytotoxic agents. Based on prior...

Go to Oxford Journals »  abstract

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition

S. Turajlic, S. J. Furney, G. Stamp, S. Rana, G. Ricken, Y. Oduko, G. Saturno, C. Springer, A. Hayes, M. Gore, J. Larkin and R. Marais.

in Annals of Oncology

May 2014; p ublished online February 2014 .

Journal Article. Subjects: Medical Oncology. 5118 words.


BRAF is mutated in ∼42% of human melanomas (COSMIC. http://www.sanger.ac.uk/genetics/CGP/cosmic/) and pharmacological BRAF inhibitors such as...

Go to Oxford Journals »  full text: open access   » abstract

Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force

I. H. Kunkler, R. Audisio, Y. Belkacemi, M. Betz, E. Gore, S. Hoffe, Y. Kirova, P. Koper, J.-L. Lagrange, A. Markouizou, R. Pfeffer and S. Villa.

in Annals of Oncology

November 2014; p ublished online March 2014 .

Journal Article. Subjects: Medical Oncology. 6985 words.

Radiotherapy (RT) is a key component of the management of older cancer patients. Level I evidence in older patients is limited. The International Society of Geriatric Oncology (SIOG)...

Go to Oxford Journals »  abstract

Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma

V. Hess, M. W. Verrill, C. C. Bomphray, M. M. Vaughan, M. Allen and M. E. Gore.

in Annals of Oncology

April 2003; p ublished online April 2003 .

Journal Article. Subjects: Medical Oncology. 3408 words.


Doxorubicin is an active compound in epithelial ovarian cancer (EOC), but adding it to carboplatin–paclitaxel causes toxicity. Toxicity can be...

Go to Oxford Journals »  abstract

Assessment of the biological and pharmacological effects of the α<sub>ν</sub>β<sub>3</sub> and α<sub>ν</sub>β<sub>5</sub> integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors

S Hariharan, D Gustafson, S Holden, D McConkey, D Davis, M Morrow, M Basche, L Gore, C Zang, CL O'Bryant, A Baron, D Gallemann, D Colevas and SG Eckhardt.

in Annals of Oncology

August 2007; p ublished online August 2007 .

Journal Article. Subjects: Medical Oncology. 5537 words.

Background: Cilengitide, an antiangiogenic agent that inhibits the binding of integrins ανβ3 and ανβ5 to the extracellular matrix, was studied at two dose levels in cancer...

Go to Oxford Journals »  abstract